The global veterinary therapeutics market was valued at US$ 25,974.2 Mn in 2016 and is projected to increase significantly at a CAGR of 6.0% from 2017 to 2026. The therapeutics drugs segment in the global veterinary therapeutics market is estimated to account for major revenue share of 55.6% in 2017.
Global Veterinary Therapeutics Market: Segmental Snapshot
According to veterinary therapeutics market infographics published on MarketResearch.Biz,
By type: Therapeutic drugs segment is estimated to register a CAGR of over 6.2%, thereby accounting for highest revenue share in the application segment.
By end-user: Hospitals segment is estimated to account for highest revenue share among the product type segments, registering a CAGR of over 6.3% over the forecast period.
By region: The market in North America accounted for highest revenue share in the global veterinary therapeutics market in 2016, and is expected to record highest CAGR of over 5.9% between 2017 and 2026.
Global Veterinary Therapeutics Market: Competitive Analysis
The research report on the global veterinary therapeutics market includes profiles of some of the major companies such as Bayer AG, Boehringer Ingelheim GmbH, Ceva, Inc., Dechra Pharmaceuticals PLC, Vetoquinol SA, Zoetis Inc., Virbac SA, Eli Lilly and Company, Merck Co. Inc., Pfizer Inc., Catalent Inc., Akorn Inc., Aratana Therapeutics, Inc., Heska Corporation, Abaxis, Inc., IDEXX Laboratories, Inc., Perrigo Company plc., NEOGEN CORPORATION, Colorado Serum Company, Piedmont Animal, Health LLC, and Addison Biological Lab, Inc.
Embed This Image On Your Site (copy code below):